Rollover Protocol for Prior SU011248 Protocols

The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pfizer Investigational Site, Randwick, New South Wales, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Prior SU011248 Protocol.
Eligible to continue SU011248 treatment.

Exclusion criteria

Uncontrolled CNS metastasis.
Unfit to receive SU011248.

Treatment and study plan

Sunitinib

Drug

Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol

Primary outcomes

Duration of Treatment

Time frame: Baseline up to Day 28 after last dose of study treatment

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol

Important dates

Study start: 2004
Primary completion: 2011
Study completion: 2011
First posted: Nov 26, 2008
Registry last updated: Jan 21, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed